Video 1: Introduction to the Daisy Petal Perfusion Bioreactor System

Sunflower Therapeutics (Sunflower), a public benefit corporation transforming global access to protein manufacturing capacity, today announced it has been awarded a Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). The Phase II award provides $2 million in funding for the over two years to support the company’s project, “Pioneering continuous cell disruption for efficient commercial scale virus-like particle (VLP) biomanufacturing”.

Sunflower® announced today that it has engaged MATSUBO Corporation as its exclusive distributor for the Daisy Petal® Perfusion Bioreactor System in Japan. This marks Sunflower’s second commercial partnership within the Asian region, representing a key step in its international growth strategy.

Daisy Petal® systems installed in GMP space to enable perfusion fermentation at SIIPL, enabling faster, higher-yield protein production in a compact, user-friendly platform.

Collaboration advances the commercialization of a 10-valent HPV vaccine.

Platform to advance the large-scale production and purification of virus-like particles (VLPs) for use in cost-effective human vaccines.

Sunflower® Therapeutics (Sunflower), a public benefit corporation transforming global access to protein manufacturing capacity for diverse applications, announced today that it has engaged Alflow Scandinavia A/S as its exclusive distributor for the Daisy Petal® Perfusion Bioreactor System in Denmark, Norway, Sweden, and Iceland. This marks Sunflower’s first commercial partnership in Europe, representing a key step in its international growth strategy.

The system is installed in the newly commissioned BioBuilder Learning Lab space in Allston Labworks for use in training local students, educators, and incumbent workers to be a passionate part of the growing biotechnology workforce.